The American Journal of Managed Care

FCM, NGS, and PCR, Oh My! Detecting MRD in Patients With Acute Lymphoblastic Leukemia

Flow cytometry (FCM), next-generation sequencing, (NGS), and polymerase chain reaction (PCR) are the 3 most common methods clinicians use to diagnose minimal residual disease (MRD) in patients with ...
Nasdaq

Adaptive Biotechnologies and Collaborators to Present Data from More Than 25 clonoSEQ® Abstracts at ASH 2019 Demonstrating Clinical Relevance of Standardized, Accurate MRD ...

SEATTLE, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune ...
The American Journal of Managed Care

FDA Clears clonoSEQ to Detect MRD in Chronic Lymphocytic Leukemia

clonoSEQ, from Adaptive Biotechnologies, can detect 1 cancer cell among a million healthy cells. Adaptive Biotechnologies received its third approval from the FDA for the use of its next-generation ...
ascopubs.org

Real-world treatment patterns in adult patients (pts) with B-cell precursor acute lymphoblastic leukemia (BCP ALL) in first hematologic complete remission (CR1) with and ...

Role of IL27 and IL35 as biomarkers and potential targets in acute myeloid leukemia. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include a full text ...